|Bid||0.904 x 1600|
|Ask||0.939 x 1000|
|Day's Range||0.890 - 0.933|
|52 Week Range||0.260 - 1.510|
|PE Ratio (TTM)||-1.23|
|Earnings Date||Mar 10, 2016 - Mar 14, 2016|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||3.40|
CARMIEL, Israel, May 25, 2017-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary ...
CARMIEL, Israel, May 23, 2017-- Protalix BioTherapeutics, Inc., announced today that an oral presentation highlighting the results from the Company’ s phase II clinical trial of alidornase alfa for the ...
Categories: Yahoo FinanceGet free summary analysis Protalix Biotherapeutics, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Protalix Biotherapeutics, Inc. – Amicus Therapeutics, Inc., Pfizer Inc., Neurocrine Biosciences, Inc. and Aviragen Therapeutics Inc (FOLD-US, PFE-US, NBIX-US and AVIR-US) that have also reported for this period. ... Read more (Read more...)